Please login to the form below
CAR-Ts
This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.
GSK’s myeloma drug hits target, prompting rapid filing pledge
Antibody drug conjugate could challenge CAR-Ts. GlaxoSmithKline has unveiled some robust data for its multiple myeloma antibody drug conjugate, and chief scientific officer Dr Hal Barron has pledged a rapid ... Celgene and Bluebird’s CAR-T bb2121 is
Latest news
-
Oxford Biomedica taps Microsoft to progress gene therapy delivery tech
It’s the approach that is used in Novartis’ Kymriah, a CAR-T therapy that was approved last year for the treatment of those with relapsed or refractory large B-cell ... lymphoma. However, Novartis was a prime example of the complex manufacturing
-
Precision BioSciences to raise $100m for off the shelf CAR-Ts
Current CAR-Ts available on the market are manufactured on a patient-by-patient basis, unique to each individual. ... Unlike typical CAR-Ts, Precision BioSciences’ one-step genomic platform uses cells from healthy donors - reducing graft versus host
-
CMS proposes coverage scheme for CAR-T therapies
The information could then be used to decide what CAR-Ts are most beneficial to patients and should be funded in future. ... So far two CAR-Ts have reached the US market, but there are dozens more coming through the clinical and preclinical pipeline.
-
AbbVie enters BCMA race with Teneobio deal
of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and also potentially producing fewer side-effects. ... The company says its platform comes with an added
-
CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL
Boysen adds: “CAR T-cell therapy is expensive, however the treatment is specific to each individual and could be a potential cure for some, although it is early days. ... CAR-Ts involve taking white blood cells from the patient, which are then
More from news
Approximately 9 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
2019: CRISPR and therapeutic gene editing comes of age
TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are
-
Deal Watch October 2018
FITC, which is not naturally present in the body, then becomes the target for CAR‐Ts expressing high affinity for FITC. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
therapies, such as CAR-Ts Kymriah and Yescarta.
-
Cancer immunotherapy: What's on the horizon?
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The CAR-Ts have transformed the treatment
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
It follows that the next generation of relationship holders, representing very expensive but ultra-personalised medicines like CAR-Ts (which are based on patients’ own cells) will be concierge-like, offering
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Health Consultant - Brand Comms
-
Competitive Salary
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Director, Medical Education
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Scientific Director – Medical Communications
-
Salary TBC
Subscribe to our email news alerts
- Fishawack acquires Dudnyk
- GSK’s myeloma drug hits target, prompting rapid filing pledge
- Winners of the HSJ Partnership Awards 2019 unveiled
- 50 questions for delivering an exceptional healthcare brand experience
- Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
- The brand strategy revolution
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
